Δ <superscript>8(14)</superscript> -Ergostenol Glycoside Derivatives Inhibit the Expression of Inflammatory Mediators and Matrix Metalloproteinase. - OpacWWW

Tytuł:: Δ -Ergostenol Glycoside Derivatives Inhibit the Expression of Inflammatory Mediators and Matrix Metalloproteinase.
Autorzy:: Moon H; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Ko M; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Park Y; Graduate School of East-West Medicinal Science, Kyung Hee University, Yongin 17104, Korea.
Kim J; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Yoon D; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Lee E; Graduate School of East-West Medicinal Science, Kyung Hee University, Yongin 17104, Korea.
Lee T; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Kim H; Global Center for Pharmaceutical Ingredient Materials, Department of Applied Chemistry, Kyung Hee University, Yongin 17104, Korea.
Źródło:: Molecules (Basel, Switzerland) [Molecules] 2021 Jul 28; Vol. 26 (15). Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI, c1995-
MeSH Terms:: Anti-Inflammatory Agents/*pharmacology
Chondrocytes/*drug effects
Ergosterol/*pharmacology
Gene Expression Regulation/*drug effects
Glycosides/*pharmacology
Synoviocytes/*drug effects
Anti-Inflammatory Agents/chemistry ; Cell Line ; Cell Survival/drug effects ; Chondrocytes/cytology ; Chondrocytes/metabolism ; Collagen Type II/genetics ; Collagen Type II/metabolism ; Ergosterol/chemistry ; Glycosides/chemical synthesis ; Humans ; Inflammation/prevention & control ; Interleukin-1beta/genetics ; Interleukin-1beta/metabolism ; Interleukin-6/genetics ; Interleukin-6/metabolism ; Interleukin-8/genetics ; Interleukin-8/metabolism ; Matrix Metalloproteinases/genetics ; Matrix Metalloproteinases/metabolism ; Models, Biological ; Nitric Oxide Synthase Type II/genetics ; Nitric Oxide Synthase Type II/metabolism ; Signal Transduction ; Synoviocytes/cytology ; Synoviocytes/metabolism ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/pharmacology
References:: Clin Rheumatol. 2019 Nov;38(11):2977-2994. (PMID: 31367943)
Osteoarthritis Cartilage. 2014 Jan;22(1):128-32. (PMID: 24185109)
Life Sci. 2019 Oct 1;234:116786. (PMID: 31445934)
Prog Mol Biol Transl Sci. 2017;148:305-325. (PMID: 28662824)
J Agric Food Chem. 2018 Dec 12;66(49):12953-12960. (PMID: 30511573)
Expert Opin Investig Drugs. 2001 Jul;10(7):1317-25. (PMID: 11772254)
Ann Rheum Dis. 2000 Jun;59(6):455-61. (PMID: 10834863)
Autoimmun Rev. 2019 Dec;18(12):102398. (PMID: 31639514)
Genet Mol Res. 2015 Nov 23;14(4):14811-22. (PMID: 26600542)
Molecules. 2019 Jan 21;24(2):. (PMID: 30669636)
J Dermatol Sci. 2015 Sep;79(3):252-61. (PMID: 26100037)
Pharm Biol. 2017 Dec;55(1):1171-1176. (PMID: 28228044)
J Asian Nat Prod Res. 2012;14(5):429-35. (PMID: 22428587)
Drug Des Devel Ther. 2018 Dec 03;12:4095-4105. (PMID: 30584274)
Br J Rheumatol. 1998 Jan;37(1):64-70. (PMID: 9487253)
Org Lett. 2003 Oct 30;5(22):4041-4. (PMID: 14572244)
Nat Commun. 2018 Nov 1;9(1):4564. (PMID: 30385786)
J Cell Physiol. 2018 Jan;233(1):409-421. (PMID: 28295306)
Nat Rev Rheumatol. 2016 Oct;12(10):580-92. (PMID: 27539668)
Curr Opin Rheumatol. 2013 Jan;25(1):108-13. (PMID: 23080227)
Biomed Pharmacother. 2018 Nov;107:397-407. (PMID: 30099344)
J Rheumatol. 2000 Jul;27(7):1606-21. (PMID: 10914841)
Life Sci. 2008 Jun 6;82(23-24):1203-9. (PMID: 18495175)
Mar Drugs. 2014 May 27;12(6):3091-115. (PMID: 24871460)
Arthritis Res Ther. 2017 Feb 2;19(1):18. (PMID: 28148295)
Nitric Oxide. 2019 Aug 1;89:32-40. (PMID: 31051258)
Int Immunopharmacol. 2018 Dec;65:119-128. (PMID: 30312880)
Biomed Pharmacother. 2019 Jan;109:1586-1592. (PMID: 30551412)
Rheumatology (Oxford). 2008 Dec;47(12):1768-70. (PMID: 18838388)
Biorheology. 2002;39(1-2):237-46. (PMID: 12082286)
Mol Nutr Food Res. 2014 Feb;58(2):256-66. (PMID: 24039109)
Front Biosci. 2006 Jan 01;11:529-43. (PMID: 16146751)
Ann Rheum Dis. 2002 Nov;61(11):975-80. (PMID: 12379519)
Grant Information:: GRRC-KyungHee2018(B01) GRRC Program of Gyeonggi province
Contributed Indexing:: Keywords: arthritis; collagen type II A1; ergostenol; ergostenol glycosides; matrix metalloproteinase
Substance Nomenclature:: 0 (Anti-Inflammatory Agents)
0 (COL2A1 protein, human)
0 (CXCL8 protein, human)
0 (Collagen Type II)
0 (Glycosides)
0 (IL1B protein, human)
0 (IL6 protein, human)
0 (Interleukin-1beta)
0 (Interleukin-6)
0 (Interleukin-8)
0 (Tumor Necrosis Factor-alpha)
EC 1.14.13.39 (NOS2 protein, human)
EC 1.14.13.39 (Nitric Oxide Synthase Type II)
EC 3.4.24.- (Matrix Metalloproteinases)
Z30RAY509F (Ergosterol)
Entry Date(s):: Date Created: 20210807 Date Completed: 20210920 Latest Revision: 20210920
Update Code:: 20240105
PubMed Central ID:: PMC8347845
DOI:: 10.3390/molecules26154547
PMID:: 34361701
: Czasopismo naukowe

Pełny tekst

Arthritis is a chronic inflammatory disease accompanied by pathological reactions such as swelling, redness, fever, and pain in various joint areas. The drugs currently available to treat arthritis are associated with diverse side-effects. Therefore, there is a need for safer and more effective treatments to alleviate the inflammation of arthritis with fewer side-effects. In this study, a new sterol, Δ 8(14) -ergostenol, was discovered, and its glycosides were synthesized and found to be more efficient in terms of synthesis or anti-inflammatory activity than either spinasterol or 5,6-dihydroergosterol is. Among these synthetic glycosides, galactosyl ergostenol inhibited the expression of inflammatory mediators in TNF-α-stimulated FLS and TNF-α-induced MMPs and collagen type II A1 degradation in human chondrocytes. These results suggest the new galactosyl ergostenol as a treatment candidate for arthritis.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja

Δ 8(14) -Ergostenol Glycoside Derivatives Inhibit the Expression of Inflammatory Mediators and Matrix Metalloproteinase.